Followed by these results, the FDA and the EMA approved new drugs, such as tisagenlecleucel [4] and axicabtagene ciloleucel [5], for the treatment of both relapsed or refractory CD19+ B-ALL and DLBCL, respectively [6]. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.